Clinical Trial Update: TAS-116 Plus Palbociclib in Breast and Rb-null Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial investigating TAS-116 in combination with palbociclib for advanced breast cancer and RB-deficient solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Breast Cancer
• Endometrial Cancer
• Retinoblastoma
• Small Cell Lung Cancer
• Soft Tissue Sarcoma

Drugs mentioned

• Palbociclib (palbociclib)
• TAS-116

Snippet

Sponsor: Brown University | Conditions: Advanced Breast Cancer, Treatment-Refractory Solid Tumors | Phase 1 | Status: WITHDRAWN